First quarter (January-March 2025)
- Operating loss amounted to SEK -8,069,404 (-5,433,422).
- Loss for the period amounted to SEK -8,013,462 (-5,369,677).
- Cash flow from operating activities totalled SEK -744,924 (-9,264,396).
- Earnings per share before and after dilution totalled SEK -0,22 (-0.26).
Key events during the quarter
- Elicera's drug candidate ELC-100 receives Orphan Drug Designation in the U.S. for the treatment of pancreatic neuroendocrine tumors.
- Elicera Therapeutics presents first clinical results from iTANK-armed CAR T-cell therapy at scientific conference: The first patient was tumor free at the first follow-up, one month after completing treatment, with no serious side effects observed.
- In March 2025 subscription of new shares with TO2 were exercised at high 96.3 %. A directed issue was made to guarantors at 3.7 %. Elicera receives 22.0 MSEK before costs.
Key events after the end of the period
- Nomination committé propose re-election of the board.
- No other key events that impact earnings or the financial position occurred after the end of the period.
CEO Comments
Elicera Therapeutics' clinical Phase I/IIa study with ELC-301 is
making significant progress and is planning to report preliminary
data during the coming year.
First patient successfully treated in the Phase I/IIa clinical study CARMA
In Phase I/IIa clinical study CARMA In early November, we were pleased to announce that the first patient had been enrolled in CARMA, the company's
Phase I/IIa clinical study aimed at documenting the safety and efficacy of our CAR T-cell candidate ELC-301 in patients with B-cell lymphoma. The study consists of
two parts: a dose-escalation study (Phase I) involving 12 patients and a dose-expansion study (Phase IIa) with 6 patients.
The cell therapy ELC-301 incorporates our platform technology iTANK, which, through its parallel immune activation, is intended to enable a broader and more effective attack on cancer cells.
At the end of January, Elicera Therapeutics presented observational data from CARMA at the scientific conference Cancer Crosslinks in Oslo, Norway. The presentation revealed that the first patient treated with ELC-301 in the study had achieved a complete response one month after treatment, with no serious side effects reported. These are promising initial data, and we are now continuing to enroll
more patients to gather clinical data for a more robust analysis.
Elicera Therapeutics' clinical Phase I/IIa study with ELC-301 is making significant progress and is planning to report preliminary data during the coming year.
We intend to report preliminary results from the study as each dosing group is completed. The company plans to present these data at scientific conferences during 2025 and 2026. The next update with preliminary efficacy data from the cohort receiving the lowest dose is planned to coincide with Professor Magnus Essand's presentation at the Swedish Cancer Research Meeting (SCRM) 2025 in Malmö
on May 22.
We also look forward to analyzing and reporting final data from the dose escalation trial in neuroendocrine tumors with ELC-100 study around mid-2025. We will thereafter communicate how we intend to proceed with the program's
development.
Strong support for the warrant program keeps the company well-capitalized
In March 2025, the subscription period for the series TO2 warrants ended, resulting in very strong support from our shareholders. Approximately 96.3 percent of outstanding warrants were exercised, providing the company with approximately SEK 22 m before issue costs. We are very pleased with this strong level of participation, which gives us an excellent opportunity to keep the company well-capitalized so that we can continue to deliver key milestones and results from the CARMA study while advancing our research. I would like to extend a big thank you to all who subscribed for shares and warmly welcome our new shareholders to Elicera.
In summary
The above highlights the significant progress Elicera Therapeutics has made as we enter an exciting 2025. I want to extend my sincere thanks to our team and partners for their outstanding work and support in getting us to this point. I also wish to express my gratitude to our shareholders for their continued trust and confidence in our journey.
Jamal El-Mosleh
CEO and co-founder
The interim report has been approved by the board and the CEO for publication. The information was submitted for publication distributed through the contact person below at 08;17 CET on May 15, 2025.
Elicera Therapeutics AB's Interim report for January to March 2025 is available at the company home page: https://www.elicera.com/investors-2/financial-reports.
For further information please contact:
Jamal El-Mosleh, CEO, Elicera Therapeutics AB
Phone: +46 (0) 703 31 90 51
jamal.elmosleh@elicera.com
Certified Advisor
Mangold Fondkommission AB
About Elicera Therapeutics AB
Elicera Therapeutics AB (publ) has developed the patented gene technology platform iTANK that enables the arming of new and existing CAR T-cell therapies targeting aggressive and relapsing cancer forms. Elicera Therapeutics thereby addresses a well-defined and vast market. The company's CAR T-cell therapies have shown a potent effect toward solid tumors which are recognized as particularly difficult to treat and constitute the majority of cancer cases. The company addresses a global multibillion market in cell therapy through its offering of non-exclusive licensing of the iTANK platform to companies in the pharmaceutical industry. Elicera Therapeutics has four internal development projects in immune therapy that separately have the potential to generate substantial value through exclusive out-licensing agreements. The company's share is traded on Nasdaq First North Growth Market. For additional information, visit www.elicera.com.
About the iTANK platform
The iTANK- (immunoTherapies Activated with NAP for efficient Killing) platform is the company's own fully developed commercially available technology platform for arming and enhancing CAR T-cells to meet two of the major challenges CAR T-cell therapies face in the treatment of solid tumors: tumor antigen heterogeneity and a hostile tumor microenvironment. The technology is used to incorporate a transgene into CAR T-cells encoding a neutrophil activating protein (NAP) from the bacterium Helicobacter pylori. Upon activation, NAP secreted from the CAR(NAP) T-cells has been shown to be able to enhance the function of the CAR T-cell in addition to activating a parallel immune response via CD8+ killer T-cells. This is expected to lead to a broad attack against most antigen targets on cancer cells. The iTANK-platform is used to enhance the company's own CAR T-cells but can also be universally applied to other CAR T-cell therapies under development. More information about iTANK-platform is available here: https://www.elicera.com/technology
